Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

Ajax Therapeutics

HQ: New York, NY source · ajaxtherapeutics.com ↗

Clinical Phase 1

Location: New York, NY · source · May 13, 2024

Profile checked Oct 10, 2026

Keywords: Primary Myelofibrosis LY5830966

1Trials (company is sponsor)

Timeline

Oct 3, 2024 Trial start 1: A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been source ↗

Upcoming milestones

2027-06 (ESTIMATED) · 1 · A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Fai · NCT06343805

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06343805	A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)	1	Recruiting	Oct 3, 2024	2027-06 (estimated)